Pharmaceutical

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to…

1 year ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical…

1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Figure: 1 Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board Carlsbad, CA, Dec. 17, 2024 (GLOBE…

1 year ago

TOMI Environmental Solutions Expands Presence in Canadian Market Through Enhanced Partnership with Betatek, Inc.

FREDERICK, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

1 year ago

NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly…

1 year ago

Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug

Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals spaceNEW YORK, Dec. 17, 2024 (GLOBE…

1 year ago

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical…

1 year ago

December 2024 Letter to Shareholders

VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc.…

1 year ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate…

1 year ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol…

1 year ago